vTv Therapeutics Inc. (NASDAQ: VTVT) is a Healthcare company (Biotechnology) with a market capitalization of $68M. The Maz Rating grades it against the other companies in its sector.
vTv Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $17.29, vTv Therapeutics Inc. trades at 551.3x trailing earnings, 1.8x sales and 2.9x book value, with an EV/EBITDA of 1.2. Over the last twelve months it generated about $39M of revenue and $123997 of net income. It runs an operating margin of -29.8% and a net margin of -20.8%. It shows return on equity of -10.1%, return on invested capital of -15.3% and a free cash flow yield of -32.6%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 11.19. Over the past 52 weeks the share price ranged from $16.71 to $44.00, with a beta of 0.26.
vTv Therapeutics Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 7 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.